Literature DB >> 23148180

Dedicated to evidence-based medicine and the evaluation of new therapeutic approaches in the field.

Christoph Schindler.   

Abstract

Year:  2011        PMID： 23148180      PMCID： PMC3474638          DOI： 10.1177/2042018811417971

Source DB:  PubMed          Journal:  Ther Adv Endocrinol Metab        ISSN： 2042-0188            Impact factor:   3.565


× No keyword cloud information.
  11 in total

Review 1.  Inflammation and metabolic disorders.

Authors:  Gökhan S Hotamisligil
Journal:  Nature       Date:  2006-12-14       Impact factor: 49.962

2.  Withdrawal of sibutramine leaves European doctors with just one obesity drug.

Authors:  Anna Sayburn
Journal:  BMJ       Date:  2010-01-25

Review 3.  [Pharmacological concepts for the treatment of obesity - a therapeutic meander?].

Authors:  C Schindler; T Chavakis; V Lamounier-Zepter; S R Bornstein
Journal:  Dtsch Med Wochenschr       Date:  2011-08-01       Impact factor: 0.628

Review 4.  Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

Authors:  Muhammad A Abdul-Ghani; Luke Norton; Ralph A Defronzo
Journal:  Endocr Rev       Date:  2011-05-23       Impact factor: 19.871

5.  Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9.

Authors:  Brandon Ason; Samnang Tep; Harry R Davis; Yiming Xu; Glen Tetzloff; Beverly Galinski; Ferdie Soriano; Natalya Dubinina; Lei Zhu; Alice Stefanni; Kenny K Wong; Marija Tadin-Strapps; Steven R Bartz; Brian Hubbard; Mollie Ranalletta; Alan B Sachs; W Michael Flanagan; Alison Strack; Nelly A Kuklin
Journal:  J Lipid Res       Date:  2011-01-24       Impact factor: 5.922

6.  Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB.

Authors:  Dongsheng Cai; Minsheng Yuan; Daniel F Frantz; Peter A Melendez; Lone Hansen; Jongsoon Lee; Steven E Shoelson
Journal:  Nat Med       Date:  2005-01-30       Impact factor: 53.440

7.  Bardoxolone methyl and kidney function in CKD with type 2 diabetes.

Authors:  Pablo E Pergola; Philip Raskin; Robert D Toto; Colin J Meyer; J Warren Huff; Eric B Grossman; Melissa Krauth; Stacey Ruiz; Paul Audhya; Heidi Christ-Schmidt; Janet Wittes; David G Warnock
Journal:  N Engl J Med       Date:  2011-06-24       Impact factor: 91.245

8.  ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.

Authors:  Christoph Schindler
Journal:  Ther Adv Cardiovasc Dis       Date:  2008-08

9.  Interleukin-1-receptor antagonist in type 2 diabetes mellitus.

Authors:  Claus M Larsen; Mirjam Faulenbach; Allan Vaag; Aage Vølund; Jan A Ehses; Burkhardt Seifert; Thomas Mandrup-Poulsen; Marc Y Donath
Journal:  N Engl J Med       Date:  2007-04-12       Impact factor: 91.245

10.  Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

Authors:  James D Lewis; Assiamira Ferrara; Tiffany Peng; Monique Hedderson; Warren B Bilker; Charles P Quesenberry; David J Vaughn; Lisa Nessel; Joseph Selby; Brian L Strom
Journal:  Diabetes Care       Date:  2011-04       Impact factor: 19.112
View more
  1 in total

1.  The Curcumin Analogs 2-Pyridyl Cyclohexanone Induce Apoptosis via Inhibition of the JAK2-STAT3 Pathway in Human Esophageal Squamous Cell Carcinoma Cells.

Authors:  Ying Wang; Pengjun Zhou; Shurong Qin; Dandan Xu; Yukun Liu; Wuyu Fu; Bibo Ruan; Li Zhang; Yi Zhang; Xiao Wang; Yuwei Pan; Sheng Wang; Haizhao Yan; Jinhong Qin; Xiaoyan Wang; Qiuying Liu; Zhiyun Du; Zhong Liu; Yifei Wang
Journal:  Front Pharmacol       Date:  2018-08-21       Impact factor: 5.810
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.